MLN120B (dihydrochloride)

MLN120B dihydrochloride (ML120B dihydrochloride) is a potent, ATP competitive, and orally active inhibitor of IKKβ with an IC50 of 60 nM. MLN120B inhibits multiple myeloma cell growth in vitro and in vivo and also can be used for the research of rheumatoid arthritis[1][2].

Product Specifications

CAS Number

[1782573-78-7]

Product Name Alternative

ML120B (dihydrochloride)

UNSPSC

12352005

Target

IKK

Type

Reference compound

Related Pathways

NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/mln120b-dihydrochloride.html

Purity

99.73

Solubility

DMSO : 16.67 mg/mL (ultrasonic; warming; adjust pH to 8 with NaOH; heat to 80°C)

Smiles

ClC1=C(C(NC(C2=CC=CN=C2C)=O)=C3C(C4=C(N3)C=NC=C4)=C1)OC.Cl.Cl

Molecular Formula

C19H17Cl3N4O2

Molecular Weight

439.72

References & Citations

[1]Hideshima T, et all. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clin Cancer Res. 2006 Oct 1;12 (19) :5887-94.|[2]Schopf L, et al. IKKbeta inhibition protects against bone and cartilage destruction in a rat model of rheumatoid arthritis. Arthritis Rheum. 2006 Oct;54 (10) :3163-73.|[3]Ansaldi D, et al. Imaging pulmonary NF-kappaB activation and therapeutic effects of MLN120B and TDZD-8. PLoS One. 2011;6 (9) :e25093.|[4][3].Nagashima K, et al. Rapid TNFR1-dependent lymphocyte depletion in vivo with a selective chemical inhibitor of IKKbeta. Blood. 2006 Jun 1;107 (11) :4266-73.